CRBU·Nasdaq·US

Caribou Biosciences

Caribou Biosciences is a clinical-stage biotechnology company focused on CRISPR genome editing and the development of allogeneic, off-the-shelf cell therapies. It also generates licensing and collaboration revenue from its genome-editing platform and partnered programs.

Create free account

Recent Activity

Updated Oct 10, 2026

–Caribou Biosciences announced it will evaluate strategic alternatives to maximize stockholder value.

–The company plans to discontinue development of its allogeneic CAR-T cell therapies vispa-cel and CB-011.

Past updates are part of the Pro plan.

Thematic Position

CRBU

Healthcare Innovation

Cell TherapyLeader

Gene Therapy & EditingLeader

Relationship Groups

Partners3

Licensing3

Competitors14

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

3 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

armed conflictpolitical instability

Armed conflicts and geopolitical tensions disrupt clinical trials and capital markets

SEC 10-KMar 5, 2026

The full regulatory passage is part of the Pro plan.